Dr. Reddy’s announces the Launch of Finasteride Tablets
Hyderabad, India, January 02, 2013
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Finasteride Tablets (1 mg), a bioequivalent generic version of Propecia® (Finasteride) Tablets in the US market on January 02, 2013. Dr. Reddy’s ANDA for Finasteride 1 mg Tablets has been awarded a 180-day period of marketing exclusivity in the U.S. on 2 Jan, 2013.
The Propecia® Tablets brand has U.S. sales of approximately $136 Million MAT for the most recent twelve months ending in October 2012 according to IMS Health*.
Dr. Reddy’s Finasteride Tablets 1 mg is available in bottle counts of 30 and 90.
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
Propecia® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
*IMS National Sales Perspectives: Retail and Non-Retail MAT October 2012
For more information please contact:
Investors and Financial Analysts:
Kedar Upadhye at email@example.com / +91-40-66834297
Saunak Savla at firstname.lastname@example.org / +91-40-49002135
Milan Kalawadia (USA) at email@example.com / +1 908-203-4931
S Rajan at firstname.lastname@example.org / +91-40-49002445